Trial Profile
Expanded Access to Navitoclax
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Venetoclax
- Indications Crohn's disease; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
- 26 Jul 2018 New trial record